Regenxbio (RGNX) Tops Q3 EPS by 10c
Tweet
Share
E-mailGet Alerts RGNX Hot Sheet
Join SI Premium – FREE
Regenxbio (NASDAQ: RGNX) reported Q3 EPS of ($1.20), $0.10 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $29.7 million versus the consensus estimate of $24.63 million.
For earnings history and earnings-related data on Regenxbio (RGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- General Mills (GIS) Tops Q1 EPS by 3c
- General Mills posts lower Q1 sales, reaffirms fiscal 2027 targets
- Veeva gains another top 20 biopharma client for its Vault CRM
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
